

RECEIVED  
CENTRAL FAX CENTER  
JUL 27 2005

19

**PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)**

Attorney Docket Number: 1008-119.US

In re Application of: BUDNY, John A.

Application Number: 09/875,997

Filed: June 6, 2001

For: "Compositions for Treating Cystic Fibrosis"

Group Art Unit: 1614

Examiner: Weddington, Kevin E.

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows:

- |   |          |
|---|----------|
| <input checked="" type="checkbox"/> One month (37 CFR 1.17(a)(1))   | \$120.00 |
| <input type="checkbox"/> Two months (37 CFR 1.17(a)(2))   | \$       |
| <input type="checkbox"/> Three months (37 CFR 1.17(a)(3))   | \$       |
| <input type="checkbox"/> Four months (37 CFR 1.17(a)(4))  | \$       |
| <input type="checkbox"/> Five months (37 CFR 1.17(a)(5))  | \$       |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Therefore the fee amount shown above is reduced by one-half, and the resulting fee is: \$ 60.00              |          |
| <input checked="" type="checkbox"/> A check in the amount of the fee is enclosed.   |          |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is enclosed.   |          |
| <input type="checkbox"/> The Commissioner has already been authorized to charge fees in this application to a Deposit Account.  |          |
| <input type="checkbox"/> The Commissioner is hereby authorized to charge fees which may be required, or credit any overpayment, to Deposit Account No . I have enclosed a duplicate copy of this sheet. |          |

I am the  assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

applicant/inventor.

attorney or agent of record

attorney or agent under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a):

Date: July 27, 2005

Signed:

Colin P. Abrahams, Registration No. 32,393

pharmacal1008-119.US40